Aptorum Group (Aptorum Group) Dividend Payout Ratio : 0.00 (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Aptorum Group Dividend Payout Ratio?

Aptorum Group's dividend payout ratio for the months ended in Jun. 2023 was 0.00.

The historical rank and industry rank for Aptorum Group's Dividend Payout Ratio or its related term are showing as below:

APM's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.43
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-29), the Dividend Yield % of Aptorum Group is 0.00%.

Aptorum Group's Dividends per Share for the months ended in Jun. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Aptorum Group Dividend Payout Ratio Historical Data

The historical data trend for Aptorum Group's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptorum Group Dividend Payout Ratio Chart

Aptorum Group Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dividend Payout Ratio

Get a 7-Day Free Trial

Aptorum Group Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Dividend Payout Ratio	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Aptorum Group's Dividend Payout Ratio

For the Biotechnology subindustry, Aptorum Group's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptorum Group's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptorum Group's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Aptorum Group's Dividend Payout Ratio falls into.

Aptorum Group Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Aptorum Group's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2022 )	/	EPS without NRI (A: Dec. 2022 )
	=	0	/	-4.278
	=	N/A

Aptorum Group's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Jun. 2023 )	/	EPS without NRI (Q: Jun. 2023 )
	=	0	/	-1.428
	=	N/A

Aptorum Group (NAS:APM) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Aptorum Group Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Aptorum Group's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptorum Group (Aptorum Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptorum Group Ltd (NAS:APM) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

17 Hanover Square, London, GBR, W1S 1BN

Website

https://www.aptorumgroup.com

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.